A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis

Journal of Rheumatology

Volumn 41, Issue 7, 2014, Pages 1366-1373

  Mohammad, Aladdin J ^a,b   Segelmark, Marten ^c,d  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Ostergotland County Council   (Sweden)

^d LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Antineutrophil cytoplasmic antibody; Endstage renal disease; Glomerulonephritis vasculitis; Survival

Indexed keywords

CREATININE; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PEROXIDASE;

ADOLESCENT; ADULT; AGE; AGED; ANTIBODY DETECTION; ANTINEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED NEPHRITIS; ARTICLE; AUTOIMMUNE DISEASE; CHILD; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE CLASSIFICATION; END STAGE RENAL DISEASE; FEMALE; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEWBORN; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; ANCA ASSOCIATED VASCULITIS; COMPARATIVE STUDY; COMPLICATION; IMMUNOLOGY; KIDNEY; MIDDLE AGED; NEPHRITIS; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; MYELOBLASTIN; NEPHRITIS; PEROXIDASE; PROGNOSIS;

EID: 84903701105     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.131038     Document Type: Article

References (26)

1. Mohammad AJ, Jacobsson LT, Westman KW, Sturfelt G, Segelmark M. Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology 2009;48:1560-5.
2. Watts RA, Scott DG, Jayne DR, Ito-Ihara T, Muso E, Fujimoto S, et al. Renal vasculitis in Japan and the UK-are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant 2008;23:3928-31.
3. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013;65:1-11.
4. Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012;367:214-23.
5. Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 2012;64:3452-62.
6. Mohammad AJ, Jacobsson LT, Mahr AD, Sturfelt G, Segelmark M. Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology 2007;46:1329-37. (Pubitemid 47244510)
7. Statistics Sweden. Population data. [Internet. Accessed April 28, 2014.] Available from: www.scb.se
8. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007;66:222-7. (Pubitemid 46226058)
9. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994;87:671-8. (Pubitemid 24334817)
10. Franssen C, Gans R, Kallenberg C, Hageluken C, Hoorntje S. Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies. J Intern Med 1998;244:209-16. (Pubitemid 28389657)
11. Jennette JC, Wilkman AS, Falk RJ. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol 1989;135:921-30. (Pubitemid 20009502)
12. Weidner S, Geuss S, Hafezi-Rachti S, Wonka A, Rupprecht HD. ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant 2004;19:1403-11. (Pubitemid 38786731)
13. Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996;7:23-32. (Pubitemid 26067088)
14. de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, Jayne DR, Gaskin G, Rasmussen N, et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol 2006;17:2264-74. (Pubitemid 44141917)
15. Schonermarck U, Lamprecht P, Csernok E, Gross WL. Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA. Rheumatology 2001;40:178-84.
16. Geffriaud-Ricouard C, Noel LH, Chauveau D, Houhou S, Grunfeld JP, Lesavre P. Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients. Clin Nephrol 1993;39:125-36. (Pubitemid 23093348)
17. Falk RJ, Hogan S, Carey TS, Jennette JC. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. Ann Intern Med 1990;113:656-63. (Pubitemid 20363637)
18. Franssen CF, Gans RO, Arends B, Hageluken C, ter Wee PM, Gerlag PG, et al. Differences between anti-myeloperoxidase-and anti-proteinase 3-associated renal disease. Kidney Int 1995; 47:193-9.
19. Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998;9:842-52. (Pubitemid 28209094)
20. de Joode AA, Sanders JS, Stegeman CA. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol 2013;8:1709-17.
21. Hauer HA, Bajema IM, van Houwelingen HC, Ferrario F, Noel LH, Waldherr R, et al. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int 2002;61:80-9. (Pubitemid 34075133)
22. Mohammad AJ, Bakoush O, Sturfelt G, Segelmark M. The extent and pattern of organ damage in small vessel vasculitis measured by the Vasculitis Damage Index (VDI). Scand J Rheumatol 2009;38:268-75.
23. Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 2010;21:1628-36.
24. Vizjak A, Rott T, Koselj-Kajtna M, Rozman B, Kaplan-Pavlovcic S, Ferluga D. Histologic and immunohistologic study and clinical presentation of ANCA-associated glomerulonephritis with correlation to ANCA antigen specificity. Am J Kidney Dis 2003;41:539-49. (Pubitemid 36278370)
25. Rihova Z, Jancova E, Merta M, Rysava R, Reiterova J, Zabka J, et al. Long-term outcome of patients with antineutrophil cytoplasmic autoantibody-associated vasculitis with renal involvement. Kidney Blood Press Res 2005;28:144-52. (Pubitemid 40981170)
26. Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011;70:488-94.